Trading in Beximco Pharmaceuticals PLC’s global depositary receipts (GDRs) – securities representing the company’s shares for international investors – resumed on the London Stock Exchange (LSE) on 26 June after the company cleared a financial reporting backlog that had put its listing at risk.
Bangladesh’s only LSE-listed company had its GDRs suspended on 2 January for failing to publish its audited financial statements for the year ended 30 June 2025 and subsequent financial reports within the exchange’s prescribed deadlines.
Under LSE rules, securities suspended for six consecutive months may be delisted if the underlying compliance issues remain unresolved. The deadline for Beximco Pharmaceuticals to restore compliance was 2 July.
According to the DSE Brokers Association of Bangladesh (DBA), foreign institutional and individual investors sought intervention from the Bangladesh Securities and Exchange Commission (BSEC) to prevent the delisting and requested the association’s support.
The DBA said it subsequently coordinated with BSEC and Beximco Pharmaceuticals’ management, after which the regulator approved a special board meeting to clear the reporting backlog.
The company then approved and published its third-quarter and audited annual financial statements for FY2024-25, together with the first, second and third-quarter financial statements for FY2025-26, enabling the LSE to lift the suspension and resume trading.
The DBA said the resumption would strengthen Bangladesh’s credibility in international capital markets and bolster foreign investor confidence.
DBA President Saiful Islam thanked Finance and Planning Minister Amir Khosru Mahmud Chowdhury, Prime Minister’s Special Assistant on Investment and Capital Market Affairs Tanvir Ghani, BSEC Chairman Masud Khan, the commission’s officials, Beximco Pharmaceuticals’ board and management and the media for their support.
The association also urged the government to continue investment-friendly policies and capital market reforms to attract more foreign investment into Bangladesh’s capital market.
